Dermatologic Therapeutics: Topical and Systemic Treatment Modalities

Topical corticosteroids represent the cornerstone of anti-inflammatory dermatologic therapy, classified into seven potency classes based on their vasoconstrictor activity. The classification ranges from Class I (superpotent) to Class VII (least potent), determining both efficacy and potential for adverse effects.

Mechanism of Action: Corticosteroids bind to cytoplasmic glucocorticoid receptors, forming complexes that translocate to the nucleus and modulate gene transcription. They suppress inflammatory mediators including prostaglandins, leukotrienes, and cytokines while reducing vasodilation, capillary permeability, and cellular infiltration.

Absorption Factors: Potency is influenced by vehicle formulation, with ointments > creams > lotions in penetration. Anatomical location significantly affects absorption: scrotum (36x) > eyelids (6x) > face (4x) > scalp (4x) > forearm (1x baseline).

Clinical Selection Principles: Choose the lowest effective potency for the shortest duration. Reserve high-potency steroids for thick, lichenified lesions or areas with low absorption. Use low-potency formulations for thin skin areas (face, inframammary, axillae, groin) and pediatric patients.

Adverse Effects: Local effects include skin atrophy, striae, telangiectasias, perioral dermatitis, and increased infection risk. Systemic absorption can cause HPA axis suppression, especially with high-potency agents, occlusive dressings, or extensive application. Tachyphylaxis may develop with continuous use, requiring drug holidays or rotation.

Contraindications: Avoid in viral, bacterial, or fungal skin infections unless used concomitantly with appropriate antimicrobials. Exercise caution in rosacea, as steroids may worsen the condition after initial improvement.

Retinoids are vitamin A derivatives that regulate cellular differentiation, proliferation, and keratinization through nuclear receptor binding. They are classified into three generations based on chemical structure and receptor selectivity.

Mechanism of Action: Retinoids bind to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression involved in cell cycle regulation, apoptosis, and immune function. They normalize follicular keratinization, reduce comedone formation, and possess anti-inflammatory properties.

Topical Retinoids: First-line therapy for comedonal acne and adjuvant for inflammatory acne. Tretinoin remains the gold standard with extensive evidence for photoaging. Adapalene offers better tolerability with once-daily dosing and available over-the-counter. Tazarotene demonstrates superior efficacy for psoriasis but higher irritation potential.

Application Guidelines: Start with lowest concentration every other night, gradually increasing frequency. Apply to clean, dry skin 20-30 minutes after washing. Use sunscreen during treatment due to increased photosensitivity. Expect 6-12 weeks for visible improvement.

Systemic Isotretinoin: Reserved for severe, scarring, or treatment-resistant acne. Dosing typically 0.5-1.0 mg/kg/day for 16-20 weeks, achieving cumulative dose of 120-150 mg/kg. Requires iPLEDGE program participation due to teratogenicity.

Monitoring Requirements: For isotretinoin, obtain baseline and monthly laboratory studies including complete blood count, liver function tests, and lipid panel. Pregnancy tests required monthly for women of childbearing potential. Screen for depression and inflammatory bowel disease symptoms.

Drug Interactions: Avoid concurrent use with tetracyclines (increased intracranial pressure risk). Vitamin A supplements should be discontinued. Topical retinoids may increase absorption of other topical agents.

Antifungal agents target various components of fungal cell membranes and metabolic pathways. Selection depends on infection type, organism, location, and patient factors including immunocompromised status.

Mechanism Classifications:

• Azoles: Inhibit 14α-demethylase, disrupting ergosterol synthesis
• Allylamines: Block squalene epoxidase, causing toxic squalene accumulation
• Polyenes: Bind ergosterol directly, creating membrane pores
• Echinocandins: Inhibit β-glucan synthesis in cell walls

Topical Agents: First-line for localized superficial infections. Azoles (clotrimazole, miconazole) effective for candidal infections and most dermatophyte infections. Terbinafine cream superior for tinea pedis and corporis. Ciclopirox offers broad spectrum including some bacterial activity.

Systemic Therapy Indications: Extensive disease, hair/nail involvement, immunocompromised patients, or failed topical therapy. Terbinafine preferred for dermatophyte infections due to fungicidal activity and tissue accumulation. Fluconazole effective for candidal infections with excellent oral bioavailability.

Treatment Durations:

• Tinea corporis/cruris: 2-4 weeks topical, 2-6 weeks oral
• Tinea pedis: 4-6 weeks topical, 2-6 weeks oral
• Onychomycosis: 3-6 months oral therapy
• Candidiasis: 1-2 weeks topical, 7-14 days oral

Monitoring and Interactions: Oral azoles require baseline liver function tests and monitoring during extended treatment. Significant CYP450 inhibition creates numerous drug interactions, particularly with warfarin, statins, and immunosuppressants. Terbinafine may cause taste disturbances and rare hepatotoxicity.

Topical antibiotics provide targeted antimicrobial therapy for superficial skin infections while minimizing systemic exposure. However, increasing resistance patterns and limited penetration restrict their clinical utility to specific indications.

Mechanism and Spectrum:

Clinical Applications: Mupirocin remains first-line for impetigo and MRSA nasal decolonization due to unique mechanism and low cross-resistance. Triple antibiotic ointments (neomycin-polymyxin-bacitracin) are appropriate for minor wound prophylaxis but carry higher contact sensitization risk.

Limitations and Concerns: Poor penetration through intact skin and biofilms limits efficacy in deeper infections. Overuse contributes to resistance development, particularly concerning for mupirocin-resistant MRSA. Contact dermatitis occurs in 1-5% of patients, highest with neomycin (10% sensitization rate).

Combination Products: Topical antibiotic-corticosteroid combinations (e.g., neomycin-polymyxin-hydrocortisone) provide anti-inflammatory and antimicrobial effects but may mask infection progression. Use cautiously and for limited duration.

Guidelines for Use: Limit treatment duration to 7-10 days to minimize resistance development. Avoid routine use for clean wounds or prophylaxis in healthy individuals. Consider systemic antibiotics for deeper infections, extensive involvement, or immunocompromised patients.

Alternative Considerations: Antiseptics like chlorhexidine or povidone-iodine may be preferred for wound cleansing. Silver-containing dressings offer antimicrobial activity without resistance concerns for chronic wounds.

Patient Education: Emphasize proper application technique, duration compliance, and signs requiring medical evaluation. Discontinue use if allergic reactions develop, characterized by increased redness, swelling, or contact dermatitis.

Systemic antibiotics play crucial roles in treating skin and soft tissue infections, acne vulgaris, and rosacea. Selection requires consideration of organism susceptibility, tissue penetration, and resistance patterns.

Anti-Acne Antibiotics: Tetracyclines demonstrate anti-inflammatory properties beyond antimicrobial activity, making them ideal for inflammatory acne. Doxycycline and minocycline show superior efficacy compared to tetracycline due to better absorption and tissue penetration.

Skin and Soft Tissue Infections (SSTI): Empiric therapy targets Staphylococcus aureus and Streptococcus pyogenes. For uncomplicated cellulitis, oral cephalexin or cloxacillin provides adequate coverage. MRSA suspicion (purulent drainage, fever, systemic toxicity) warrants clindamycin, doxycycline, or trimethoprim-sulfamethoxazole.

Dosing Considerations:

• Doxycycline: 40-100 mg twice daily (acne), 100 mg twice daily (infections)
• Minocycline: 50-100 mg twice daily (extended-release available)
• Cephalexin: 500 mg four times daily or 1000 mg twice daily
• Clindamycin: 150-300 mg every 6-8 hours

Adverse Effects: Tetracyclines cause photosensitivity, esophageal irritation, and rare autoimmune reactions (minocycline). Avoid in pregnancy and children <8 years due to tooth discoloration. Clindamycin carries 10-20% risk of C. difficile-associated diarrhea.

Resistance Patterns: P. acnes resistance to erythromycin and clindamycin approaches 50% in many regions. Combination with benzoyl peroxide reduces resistance development. MRSA prevalence varies geographically but exceeds 50% in many areas.

Duration and Monitoring: Acne treatment typically requires 3-6 months with gradual tapering. Monitor for improvement at 6-8 weeks. SSTI treatment duration is 7-14 days based on clinical response. Longer courses may be needed for complicated infections or diabetic patients.

Biologic agents represent revolutionary targeted therapies for immune-mediated dermatologic conditions, particularly psoriasis, atopic dermatitis, and hidradenitis suppurativa. These large-molecule drugs target specific inflammatory pathways with remarkable efficacy.

TNF-α Inhibitors: First-generation biologics that neutralize tumor necrosis factor-alpha, a key pro-inflammatory cytokine.

IL-17 Pathway Inhibitors: Target the IL-17/IL-23 axis, crucial in psoriasis pathogenesis.

• Secukinumab: IL-17A inhibitor, 300 mg SC at weeks 0, 1, 2, 3, 4, then monthly
• Ixekizumab: IL-17A inhibitor, 160 mg SC initial dose, then 80 mg q4w
• Ustekinumab: IL-12/IL-23 inhibitor, weight-based dosing q12w after initial doses

IL-23 Specific Inhibitors: Newer agents with potentially superior long-term efficacy.

• Guselkumab: 100 mg SC at weeks 0, 4, then q8w
• Tildrakizumab: 100 mg SC at weeks 0, 4, then q12w
• Risankizumab: 150 mg SC at weeks 0, 4, then q12w

Atopic Dermatitis Biologics:

• Dupilumab: IL-4/IL-13 inhibitor, 600 mg SC initial, then 300 mg q2w
• Tralokinumab: IL-13 inhibitor, 300 mg SC q2w initially, then q4w

Efficacy Measures: Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responses represent 75%, 90%, and 100% improvement from baseline. IL-17 and IL-23 inhibitors achieve PASI 90 in 60-80% of patients at week 12-16.

Safety Profile: Increased infection risk, particularly upper respiratory tract infections. Tuberculosis screening (chest X-ray, interferon-gamma release assay) required before initiation. Live vaccines contraindicated during treatment.

Monitoring Requirements: Baseline complete blood count, liver function tests, hepatitis B/C, and tuberculosis screening. Periodic monitoring for infections, malignancy, and injection site reactions. Annual skin cancer screening recommended.

Cost and Access: Biologics are expensive ($50,000-80,000 annually) but demonstrate cost-effectiveness in severe disease through improved quality of life and reduced healthcare utilization.

Dermatologic therapeutics require careful consideration in special populations and potential drug interactions, particularly with systemic agents and immunosuppressive biologics.

Pregnancy Considerations:

Pediatric Considerations: Children have thinner skin with increased absorption rates. Use lowest potency corticosteroids for shortest duration. Avoid tetracyclines under age 8. Calculate biologic dosing by weight, with limited pediatric approval for most agents.

Geriatric Population: Age-related skin thinning increases corticosteroid absorption and atrophy risk. Reduced hepatic metabolism affects oral antifungal clearance. Polypharmacy increases drug interaction potential, particularly with azole antifungals.

Immunocompromised Patients: Enhanced infection risk with topical and systemic antibiotics. Biologics require additional screening and monitoring. Consider prophylactic antifungals in severely immunosuppressed patients.

Significant Drug Interactions:

• Azole antifungals: Potent CYP3A4 inhibitors affecting warfarin, statins, cyclosporine
• Isotretinoin: Avoid tetracyclines (increased intracranial pressure), vitamin A supplements
• Biologics: Live vaccines contraindicated, may reduce effectiveness of inactivated vaccines

Hepatic Impairment: Dose reduction required for oral antifungals and isotretinoin. Increased monitoring necessary for hepatotoxic agents. Topical therapy preferred when possible.

Renal Impairment: Dose adjustments needed for systemically absorbed agents. Monitor for accumulation with prolonged topical use of aminoglycosides.

Patient Counseling Points: Emphasize proper application techniques, duration compliance, and sun protection. Discuss realistic expectations for treatment timelines. Provide written instructions for complex regimens and monitoring requirements.

Quality of Life Considerations: Dermatologic conditions significantly impact psychological well-being. Consider patient preferences, lifestyle factors, and treatment burden when selecting therapies. Support groups and psychological counseling may be beneficial adjuncts.